If you or someone you love has been diagnosed with macular degeneration, you have almost certainly received the same answer from every eye specialist: "There is no cure — we can only try to slow the progression." For the millions of Americans living with age-related macular degeneration (AMD), those words have become a familiar and deeply discouraging sentence.

But what if the full picture of AMD — specifically, what drives retinal cell decline at a cellular level — is more nuanced than most patients are ever told? A growing body of peer-reviewed research, including 47 independent studies published between 1999 and 2018, has been pointing toward a potential role for marine-derived antioxidants in supporting retinal cell health. These findings have received remarkably little attention in mainstream eye care — and a retinal specialist who himself was diagnosed with aggressive macular degeneration at age 47 has recently stepped forward to explain why.

"In 15 years of practice treating thousands of patients with vision loss, I had never once focused on the core question: what is actually driving retinal cell decline at the source?"

After his diagnosis, this specialist dove deep into the foundational biochemistry literature — not the standard treatment protocols, but the studies that examine what happens to retinal cells under oxidative stress, and what compounds have shown the most promise in protecting them. What he found was a body of research on marine-derived antioxidants — particularly astaxanthin and fucoxanthin — that had been sitting largely unnoticed in scientific journals for over two decades.

The central mechanism is well documented: retinal cells are among the most metabolically active in the human body, and they are under constant assault from reactive oxygen species — free radicals that accumulate faster as we age. By the time most people are diagnosed with dry macular degeneration or wet macular degeneration, oxidative damage to the macula has been building for years. Standard treatments address the consequences of that damage — leaking vessels, swelling, tissue loss — but not the underlying oxidative process itself.

The studies this specialist reviewed suggested something different: that certain marine compounds, when properly stabilized and delivered, may be able to support the cellular environment of the macula in ways that slow — and in some cases appear to help reverse — the oxidative deterioration that underlies age-related macular degeneration. The presentation linked below covers the science in detail, including the specific compounds involved, the bioavailability challenge that has historically limited their use, and what the clinical observations showed.

The accounts from people who explored this approach are striking. A 71-year-old woman with advanced AMD described going from struggling to make out shapes to reading full chapters of a book again. A 67-year-old man with significant peripheral vision loss reported watching his grandson play baseball from the bleachers — something he had given up on entirely. Many people who had been adjusting to the reality of progressive vision loss describe meaningful changes in their daily visual function.

This is a presentation for anyone living with macular degeneration, caring for someone who is, or simply trying to understand what the research actually says about retinal degeneration and natural support for eye health. The specialist explains the science clearly, without oversimplification — click here or tap the button below to watch the full presentation.